The CRO departure explicitly tied to commercial underperformance is a near-term negative for CVRX. Monitor for any preliminary Q3 revenue updates or guidance revisions in the coming weeks, as the sales leadership vacuum could pressure near-term bookings. The interim appointment of an internal veteran mitigates some disruption risk.
Price Chart
Executive Summary
CVRx terminated Chief Revenue Officer Robert John effective immediately, citing a 'revised commercial outlook' and need to improve commercial execution. Paul Verrastro, a 30-year med-device veteran and former CMO/Strategy Officer, has been named Interim Head of Sales while the company searches for a permanent successor. The departure of the top sales executive amid acknowledged commercial struggles is a negative signal for a commercial-stage company with a $63M market cap, though the immediate appointment of an internal interim leader provides some continuity.
Key Facts
- Chief Revenue Officer Robert John terminated effective August 10, 2026, with severance.
- CEO Kevin Hykes cited 'revised commercial outlook and need to improve commercial execution' as reasons for the change.
- Paul Verrastro named Interim Head of Sales; he has 30+ years of med-device experience and was previously CMO/Strategy Officer at CVRx.
- A search for a permanent successor is underway.
Financial Impact
No financial figures provided in the filing. The change signals potential revenue headwinds for a commercial-stage company.
Risk Factors
- Extended sales leadership vacuum could further pressure revenue growth
- Potential for additional commercial restructuring or cost-cutting measures
- Competitive pressure in the heart failure neuromodulation market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-093721 |
| Document: tm2622791d1_ex99-1.htm | 0001104659-26-093721 |
| Document: 0001104659-26-093721-index-headers.html | 0001104659-26-093721 |
| Document: 0001104659-26-093721-index.html | 0001104659-26-093721 |
| Document: 0001104659-26-093721.txt | 0001104659-26-093721 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $1.37 | awaiting T+5 | — | $1.41 (+3.28%) |
Oct 2, 2026 24d ago | SC 13D/A | $1.56 $1.48 | ▲ +5.13% | ▲ +5.55% | $1.41 (+9.29%) |
Aug 11, 2026 11w ago | 8-K | $2.60 $2.75 | ▼ −5.77% | ▼ −6.17% | $1.41 (+45.58%) |
Jul 23, 2026 13w ago | Press Release | $4.74 $5.38 | ▲ +13.50% | ▲ +13.13% | $1.41 (−70.15%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.03 $4.95 | ▼ −1.59% | ▼ −2.26% | $1.41 (−71.87%) |
Jun 9, 2026 20w ago | 8-K | $5.20 $4.98 | ▼ −4.23% | ▼ −6.64% | $1.41 (−72.79%) |
Jun 9, 2026 20w ago | Press Release | $5.20 $4.98 | ▼ −4.23% | ▼ −6.64% | $1.41 (−72.79%) |
Jun 3, 2026 20w ago | 3 | $5.88 $4.89 | ▼ −16.84% | ▼ −14.28% | $1.41 (−75.94%) |
May 11, 2026 24w ago | 8-K | $5.27 $5.94 | ▲ +12.71% | ▲ +12.64% | $1.41 (−73.15%) |
Apr 27, 2026 26w ago | Press Release | $7.48 $7.80 | ▲ +4.21% | ▲ +2.52% | $1.41 (−81.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers